The 2023 Florida Statutes (including Special Session C)
|
||||||
|
. . . . § 601.51, no data or information in a CBER IND file is available for public disclosure before FDA approves . . .
. . . . §§ 600-601.51 (1988), a biological substance such as EPO can be sold in the United States only after . . .
. . . 45% Reduction (d) Reasonable Fee (a x c) Riggins $90 1465.35 805.94 $ 72,534.60 Pollard 93 1093.65 601.51 . . .